Vivaldi Capital Management’s Aimmune Therapeutics AIMT Stock Holding History

Vivaldi Capital Management’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-10,556	Closed	-$364K	–	352
2020 Q3	$364K	Buy	+10,556	New	+$225K	0.08%	169

Vivaldi Capital Management's AIMT Position: Q4 2020 in Review

Vivaldi Capital Management sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 10,556 shares — an estimated $364K sold.

Vivaldi Capital Management first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $364K in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Vivaldi Capital Management reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Vivaldi Capital Management sold 10,556 Aimmune Therapeutics shares in Q4 2020, an estimated $364K.
Vivaldi Capital Management first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Vivaldi Capital Management's Aimmune Therapeutics position peaked at $364K in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Vivaldi Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.